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Background
One of the most troublesome features of atopic dermatitis
(AD) is its chronic relapsing nature. The long-term
efficacy and potential of corticosteroids to reduce or pre-
vent relapses have only partially been addressed, especially
in children. This study was designed to compare an inter-
mittent dosing regimen of fluticasone propionate (FP)
cream 0.05% (twice per week) with its vehicle base in
reducing the risk of relapse in paediatric subjects with
stabilized AD.
Methods
Randomized controlled, multicentric, double blind trial
was conducted. Severity of AD was scored by means of
the modified Scoring of Atopic Dermatitis system
(SCORAD). Children (2-10 years) with mild or moderate
AD (SCORAD up to 50; exclusion criteria were >30%
affected body surface area and/or head) were enrolled into
an Open-label Stabilization Phase (OSP) of up to 2 weeks
on twice daily FP. Those children who achieved treatment
success (SCORAD<5or≥75% initial SCORAD) entered
the Double-blind Maintenance Phase (DMP). They were
randomly allocated to receive FP or vehicle twice weekly
on consecutive days for 16 weeks. The primary study
endpoint was relapse rate of AD, time to relapse and
severity of disease were also studied. Kaplan–Meier esti-
mates were calculated to describe the time to relapse
distribution. The study protocol was approved by the
Ethics Committee and all patients’ parents provided their
written informed consent.
Results
Fifty-four patients (29 girls) entered the OSP (23 mild
AD) and 49 (26 girls) continued into the DMP. Mean age
was 5.5 (SD2.8) and 5.1 (SD2.3) yrs for FP and vehicle
groups, respectively. Four patients withdrew from the
DMP (two in the FP group and two in the vehicle group).
Patients treated with FP twice weekly had a 2.7 fold
lower risk of experiencing a relapse than patients treated
with vehicle (relative risk 2.72, SE1.28; p=0.034). FP was
also superior to vehicle for delaying time to relapse
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(Mean 108.4 SD32.5 and Mean 77.4 SD54.6, respectively).
Therapy with both treatments was well tolerated.
Conclusions
This long-term study shows that twice per week FP pro-
vides an effective maintenance treatment regimen to con-
trol AD through a significantly reduction of the risk of
relapse in children with mild and moderate AD.
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